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Available online 12 November 2015Since the non-vitamin K antagonist oral anticoagulants (NOACs) have been introduced to clinical practice, there
is a conﬂict on coagulation tests, which have been used to monitor the anticoagulation effect of vitamin K antag-
onists (VKAs) and unfractionated heparin (UFH). NOACs have alternative modes of action. They react differently
than VKAs and UFH and therefore conventional coagulation tests are not suitable to monitor their anticoagulant
effect. The interactions between NOACs and routine coagulation tests are discussed in this review.
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Many anticoagulant agents are available for prevention and treat-
ment of thromboembolic disorders such as thewarfarin derivatives (vi-
tamin K antagonists—VKAs), unfractionated heparin (UFH) and low
molecular weight heparins (LMWHs).1,2 In the last decade a new class
of anticoagulant drugs has been developed for clinical use. The non-
vitamin K antagonist oral anticoagulants (NOACs) are orally active and
inhibit coagulation serine proteases selectively and speciﬁcally.3 Unlike
VKA and UFH,4,5 the NOACs such as dabigatran (direct thrombin inhib-
itor), rivaroxaban, apixaban and edoxaban (all direct Factor Xa inhibi-
tors) do not require routine coagulation monitoring because they have
a rapid onset of action, their therapeuticwindow iswide and their phar-
macokinetics and pharmacodynamics are predictable.6,7 However in
some clinical situations the need for assessment of the anticoagulant ef-
fect of these new agents might arise, which requires an understanding
of the different mechanism of action of each agent and their implica-
tions when interpreting routine coagulation tests are necessary.1 The
most commonly used clot-based tests are prothrombin time (PT)/inter-
national normalized ratio (INR) and activated partial thromboplastindiovascular Academy.
my. Production and hosting by Elsetime (aPTT).1 PT is the time in seconds for plasma to coagulate after ad-
dition of calcium and an activator of the extrinsic pathway of the coag-
ulation cascade as thromboplastin.8 PT is mostly used to monitor VKAs
which inhibits factors II, VII and X.9 Because of varying sensitivities of
the available thromboplastin agents, PT is converted to INR through a
mathematical formula that includes the International Sensitivity Index
(ISI) of the thromboplastin reagent used. ISI is obtained from the
manufacturer.10 After the calculation, INR can be interpreted without
regard to the thromboplastin reagent.8 While aPTT is similar to PT,
aPTT reﬂects the presence and activity of factors II, V, VIII, XII and
ﬁbrinogen.8 Therefore, the test is used to measure the overall function
of the intrinsic coagulation pathway.1 However these tests do not
react in the same way for NOACs and may be misinterpreted by non-
expert clinicians.1,3Dabigatran
The PT is relatively insensitive to dabigatran and the PT reagent sen-
sitivity is extremely variable.11,12 The INR/ISI calculation which is used
for warfarin derivatives is not suitable for dabigatran. The contradiction
between PT results is increased by point of care-derived INR results.13,14vier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
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and shows a curvilinear dose response with an increase at low concen-
trations and linearity at high concentration.12,15 The aPTT results are in-
ﬂuenced by coagulometers and reagents and need to be evaluated
carefully. In the nationwide Belgian survey, Actin FSL is found the least
sensitive among aPTT reagents. The other reagents (Actin FS, APTT-SP,
STA-CK Prest, STA-Cephascreen, STA-PTT A, SynthASil and TriniCLOT
aPTT HS) used in the survey show slightly higher sensitivities.21
A normal aPTT can presumably exclude a therapeutic intensity of
dabigatran but cannot exclude some degree of anticoagulation caused
by dabigatran.3 If the aPTT level at trough exceeds two times the upper
limit of normal, this can be considered as a higher risk of bleeding.16
Rivaroxaban
Rivaroxaban plasma levels in healthy subjects correlate closely with
the inhibition of Factor Xa activity and prolongation of PT and aPTT.17,18
The PT is more sensitive for rivaroxaban. There is a linear concentra-
tion–response correlation but because of the high variability between
PT reagents, up to three-fold difference between them can be
observed.3,19 The INR calculation increases the contradiction between
PT results (nearly four-fold), because ISI are calculated for VKAs, and
therefore INR results should not be used.1,3,19 A normal PT level cannot
exclude some degree of anticoagulation effect but a normal PT level
achieved with most reagents excludes a therapeutic intensity of
rivaroxaban.3 With the thromboplastin reagents, neoplastin and
neoplastin plus, the PT is inﬂuenced in a dose-dependent manner with
a close correlation to plasma concentrations.16 In the Belgian survey,
where six different PT reagents were used, the reagents Innovin and
Thrombel S were found least sensitive to rivaroxaban and Neoplastin
Rwas themost sensitive PT reagent to rivaroxaban.21 The sensitivity dif-
ferencewas not connectedwith the source of tissue factor and it may be
related to the composition of the reagents.21
Apixaban
Apixaban prolongs PT in human plasma in vitro.20 As with
rivaroxaban, there is variability in the PT sensitivity between thrombo-
plastin reagents and the INR calculation increases variability.3,19 To
measure the inhibition of Factor Xa activity gives a better sign of
apixaban plasma concentration than a PT test.19
Apixaban has been shown to prolong the aPTT in a concentration de-
pendentmanner in vitro but the aPTT test is not sensitive to apixaban.1,20
Discussion
In clinical practice NOACs are prescribed at ﬁxed doses and do not
require routine coagulation monitoring, but their presence can affect
routine coagulation tests especially in high-doses or if the blood sample
is taken at thepeakplasma concentration level and thesemay lead to in-
terpret the test results improperly.21 NOACs prolong the PT and aPTT in
a concentration- and reagent-dependent manner. There is a signiﬁcant
difference in sensitivity of reagents. PT reagents are more inﬂuenced
by rivaroxaban and apixaban and aPTT reagents are more inﬂuenced
by dabigatran.21 In monitoring VKA therapy, PT results are expressed
as INR levels commonly in daily clinical practice. However for NOACs,converting PT to INRdoes not decrease but even increases the variability
between reagents and cannot be applied because the conventional INR
system was developed to monitor VKAs and correct the varying sensi-
tivities of reagents for VKAs, not for NOACs.21
Conclusion
It is important for clinicians to appreciate the variable effects of indi-
vidual NOACs on PT and aPTT reagents utilized to avoid erroneous inter-
pretation of results.
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